New7

ADC Related

ADC Antibody ADC Cytotoxin ADC Linker ADCs Drug-Linker Conjugates for ADC
Angiogenesis

5-alpha Reductase ALK Bcr-Abl BTK EGFR FAK FLT3 HER-2 HIF Src Syk VDA VEGFR
Anti-infection

Antibiotic Arenavirus Bacterial CMV EBV Enterovirus Filovirus Fungal Gli HBV HCV HCV Protease HIV HSV Influenza Virus Parasite RABV Reverse Transcriptase RSV SARS-CoV TMV Virus Protease
Apoptosis

Apoptosis ASK Bcl-2 Caspase c-Myc c-RET Cytohesin DAPK Ferroptosis FKBP IAP Mdm2 p53 PD-1 PD-L1 PERK PKD Ras RIP kinase ROS Survivin Thymidylate Synthase TNF Receptor TNFa TRADD
Autophagy

Autophagy LRRK2 Mitophagy OGA ULK
Cell Cycle

Antifolate APC Aurora Kinase BMI-1 CDK Chk c-Myc Eukaryotic Initiation Factor G-quadruplex HDAC HSP Kinesin LIMK Mad2 Microtubule(Tubulin) Mps1 Nucleoside Antimetabolite/Analog Nur77 p21 PAK PERK PFKFB PLK PPAR Ras Rho ROCK SRPK TOPK Topoisomerase Wee1
Cytoskeletal Signaling

Arp2 3 Complex Bcr-Abl Cardiac Myosin Dynamin Gap Junction Protein HSP Integrin Kinesin Microtubule Associated MLCK Myosin PAK TACC3 Wntbeta-catenin
DNA Damage

ATM(ATR) CRISPR(Cas9) DNA alkylator DNA Stain DNA(RNA) Synthesis GAK HDAC HSP Nucleoside Antimetabolite(Analog) OGG1 p97 PARG PARP RAD51 RNR Sirtuin SMN Telomerase Topoisomerase
Endocrinology & Hormones

5-alpha Reductase ACE Adrenergic Receptor Androgen Receptor Aromatase Estrogenprogestogen Receptor Glucocorticoid Receptor GPR Mineralocorticoid Receptor RAAS THR TSH Receptor
Epigenetics

AMPK Aurora Kinase DNA Methyltransferase Epigenetic Reader Domain EZH1 2 HDAC HIF Histone Acetyltransferase Histone Demethylase Histone Methyltransferase JAK MAT MicroRNA MLL Pim PKC Protein Arginine Deiminase Sirtuin Small Interfering RNA (siRNA) SMYD

+MORE

New7

New7 related products

Cat No.	Product Name	CAS No.	Product Description
V4612	SB269652	215802-15-6	SB269652 is a novel and potent drug-like allosteric modulator of the dopamine D2 receptor (D2R).
V4613	SB756050	447410-57-3	SB756050 is a novel, potent and selectiveTGR5agonist which is currently under investigation in phase 1 clinical trials for the treatment of type 2 diabetes.
V4665	Sch-42495	136511-43-8	Sch-42495, the orally bioactive ethylester prodrug of SCH 42354, is a novel and potent inhibitor of neutral metalloendopeptidase (NEP).
V4668	SCH-546738	906805-42-3	SCH-546738 (SCH546738) is a novel, potent selective, and non-competitive CXCR3 antagonist with potential anticancer, immunomodulatory and antiinflammatory activities.
V4672	SCH28080	76081-98-6	SCH-28080 (SCH 28080) is a novel, potent and competitive inhibitor of gastric H+ and K+-ATPase withgastric antisecretory and cytoprotective activities.
V4671	Sch412348	377727-26-9	SCH 412348 (SCH-412348) is a novel and potent competitive antagonists of the human A(2A) receptor (K(i) = 1.1 and 0.6 nM, respectively) with potential anti-PD (Parkinson disease).
V4669	Sch59498	224157-99-7	Sch59498 is a novel and potentphosphodiesterase 1c (Pde1c) inhibitor that has the potentialfor treating or ameliorating an effect of proximal spinal muscular atrophy (SMA) and for preventing or slowing motor neuron death in a subject having SMA.
V5131	SJG-136 (NSC-694501)	232931-57-6	SJG-136 (NSC694501), anovel sequence-selective pyrrolobenzodiazepine (PBD) dimer, is a novel and potent DNA cross-linking/intercalating agent with an XL50of 45 nM for pBR322 DNA; SJG-136 has potent anticancer activity and can be potentially used for the treatment of ovarian cancer and leukemia.
V4536	SNIPER(ABL)-024	2222355-77-1	SNIPER(ABL)-024 is a compound by conjugating GNF5 (an ABL inhibitor) to LCL161 derivative (IAP-inhibitor of apoptosis protein ligand) with a linker, induces the reduction of BCR-ABL protein with a DC50of 5μM.
V4950	SR 11237	146670-40-8	SR11237 (BMS-649) is a retinoid X receptor (RXR) selective agonist without any RAR activity.
V5163	SR142948A	184162-64-9	SR 142948A is a novel non-peptide Neurotensin receptor antagonist used in scientific research.
V5115	Symadex (XLS002, C1311)	138154-39-9	Symadex (formerly XLS-002, C-1311, andimidazoacridone) is a novel anticancer agent of the imidazoacridinone class which has been recommended for Phase II clinical trials a few years ago, it has shown activity in experimental tumour models both in vitro and in nude mice.
V4588	SYR-127063	871026-18-5	SYR127063 (also known as BDBM92454) is a novel, potent and selective HER2 inhibitor with IC50 of 11 nM, 429 nM,> 10000 nM for HER2, EGFR, and HER4, respectively.
V4580	TAK-024	186971-69-7	TAK-024 is a novel and potentplateletinhibitor withIC50s of 31, 79 and 51 nM in human, monkey and guinea pig, respectively.
V4583	TAK-071	1820812-16-5	TAK-071 is a novel, potent and highly selectivemuscarinic acetylcholine receptor 1 (M1R)positive allosteric modulator (PAM).
V4591	TAK-220	333994-00-6	TAK-220 (TAK220), a novel 1,4-disubstituted piperidine/piperazine, is a potent, selective and orally bioavailableCCR5antagonist withIC50s of 3.5 nM and 1.4 nM for inhibition on the binding of RANTES and MIP-1α to CCR5, respectively.
V4584	TAK-778	180185-61-9	TAK-778, a derivative of ipriflavone, has been shown to induce bone growth both in vitro and in vivo.
V4587	TAK-828F	1854901-94-2	TAK-828F (TAK828F) is a novel, potent, selective, and orally bioavailable retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonist with bindingIC50of 1.9 nM and reporter geneIC50of 6.1 nM.
V4586	TAK-981	1858276-04-6	TAK-981 is a novel, potent and selectivesmall molecule inhibitor of sumoylation with potential immune-activating and antineoplastic activities.
V4589	TAK1/MAP4K2 inhibitor 1	1315330-11-0	TAK1/MAP4K2 inhibitor 1 is a novel, potent dual TGFβ-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2) inhibitor, withIC50s of 41.1 nM and 18.2 nM, respectively.